Federal Register / Vol. 84, No. 18 / Monday, January 28, 2019 / Notices 427 

probability of causation guidelines 

which have been promulgated by the 

Department of Health and Human 

Services (HHS) as a final rule, advice on 

methods of dose reconstruction which 

have also been promulgated by HHS as 

a final rule, advice on the scientific 

validity and quality of dose estimation 

and reconstruction efforts being 

performed for purposes of the 

compensation program, and advice on 

petitions to add classes of workers to the 

Special Exposure Cohort (SEC). In 

December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, 

which subsequently delegated this 

authority to the CDC. NIOSH 

implements this responsibility for CDC. 

The charter was issued on August 3, 

2001, renewed at appropriate intervals, 

rechartered under Executive Order 

13811 on February 12, 2018, and will 

terminate on March 22, 2020. 

Purpose: This Advisory Board is 

charged with (a) providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advising the Secretary 

on whether there is a class of employees 

at any Department of Energy facility 

who were exposed to radiation but for 

whom it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. 

Matters to be Considered: The agenda 

will include discussions on: Recording 

December 2018 Meeting Absentee Votes; 

Work Group and Subcommittee Reports; 

Update on the Status of SEC Petitions; 

Plans for the April 2019 Advisory Board 

Meeting; and Advisory Board 

Correspondence. Agenda items are 

subject to change as priorities dictate. 

The Chief Operating Officer, Centers 

for Disease Control and Prevention, has 

been delegated the authority to sign 

Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2019–00196 Filed 1–25–19; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public, limited only by room seating. 

The meeting room accommodates 216 

for public seating. Rooms 245, 246, and 

247, adjacent to the meeting room, will 

be available once the meeting room 

reaches capacity, providing up to 120 

additional seats. Time will be available 

for public comment. The meeting will 

be webcast live via the World Wide 

Web; for instructions and more 

information on ACIP please visit the 

ACIP website: http://www.cdc.gov/ 

vaccines/acip/index.html. 

DATES: The meeting will be held on 

February 27, 2019, 8:00 a.m. to 5:30 

p.m., EST, and February 28, 2019, 8:30 

a.m. to 3:30 p.m. EST. 

ADDRESSES: CDC, 1600 Clifton Road, 

NE, Tom Harkin Global 

Communications Center, Building 19, 

Kent ‘Oz’ Nelson Auditorium, Atlanta, 

Georgia 30329–4027. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, CDC, NCIRD, 

telephone 404–639–8836, email ACIP@

cdc.gov. 

SUPPLEMENTARY INFORMATION:

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the Director of the 

Centers for Disease Control and 

Prevention and appear on CDC 

immunization schedules must be 

covered by applicable health plans. 

Public Comment 

Oral Public Comment: This meeting 

will include one 75-minute session for 

oral public comment during which 

members of the public may make an inperson public comment. The oral public 

comment session will occur near the 

end of the first day’s session on 

February 27, 2019 and before any 

scheduled votes including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. On-site, in-person registration for 

oral public comment at the meeting will 

only be available if there is time 

remaining in the oral public comment 

session after all individuals who 

submitted a request to make an oral 

comment before the meeting have had 

an opportunity to speak. There is no 

guarantee there will be an opportunity 

for on-site, in-person registration for 

oral public comment, and all 

individuals interested in requesting to 

make an oral public comment are 

strongly encouraged to submit a request 

according to the instructions below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the February ACIP 

meeting must submit a request at http:// 

www.cdc.gov/vaccines/acip/meetings/ 

no later than 11:59 p.m., EDT, February 

13, 2019. Interested persons must 

include their name; the name of the 

group or organization the individual is 

representing, if applicable; and contact 

information, including email address, 

mailing address, and telephone number. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

75-minute oral public comment session, 

CDC will conduct a lottery to determine 

the speakers for the scheduled session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by February 15, 2019. To accommodate 

the significant interest in participation 

in the oral public comment session of 

ACIP meetings, each speaker will be 

limited to 3 minutes, and each speaker 

may only speak once per meeting. 

Interested persons who are unable to 

make an oral public comment during 

this meeting are invited to submit a 

written comment according to the 

instructions below. 

Written Public Comment: Written 

comments will be accepted up to 48 

hours following the end of the ACIP 

Meeting. You may submit comments, 


amozie on DSK3GDR082PROD with NOTICES1
428 Federal Register / Vol. 84, No. 18 / Monday, January 28, 2019 / Notices 

identified by Docket No. CDC–201x– 

xxxx using the Federal eRulemaking 

Portal: http://www.regulations.gov. 

Follow the instructions for submitting 

comments. All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received in conformance with the 

regulations.gov suitability policy will be 

posted without change to http://

regulations.gov, including any personal 

information provided. For access to the 

docket to read background documents 

or comments received, go to http://

www.regulations.gov. Written public 

comments submitted by 72 hours prior 

to the ACIP meeting will be provided to 

the ACIP members before the meeting. 

Matters to be Considered: The agenda 

will include discussions on human 

papillomavirus vaccines, pneumococcal 

vaccines, Japanese encephalitis 

vaccines, influenza vaccines, anthrax 

vaccine, hepatitis vaccines, Pertussis 

vaccine, herpes zoster vaccine, and 

meningococcal vaccines. A 

recommendation vote is scheduled for 

anthrax vaccine, Japanese encephalitis 

vaccines, and human papillomavirus 

vaccines. Agenda items are subject to 

change as priorities dictate. For more 

information on the meeting agenda visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/meetings-info.html. 

The Chief Operating Officer, Centers 

for Disease Control and Prevention, has 

been delegated the authority to sign 

Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri A. Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2019–00197 Filed 1–25–19; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Chief Operating Officer, CDC, 

pursuant to Public Law 92–463. The 

grant applications and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the grant applications, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of privacy. 

Name of Committee: Disease, Disability, 

and Injury Prevention and Control Special 

Emphasis Panel; (SEP)—PAR 15–303, 

Occupational Safety and Health Education 

and Research Centers (ERC). 

Dates and Times: February 11, 2019, 6:00 

p.m.–8:00 p.m. EST, February 12–13, 2019, 

8:30 a.m.–5:00 p.m. EST. 

Place: Hilton Alexandria Old Town, 1767 

King Street, Alexandria, Virginia 22314, 

(703)837–0440. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Michael 

Goldcamp, Ph.D., Scientific Review Officer, 

Office of Extramural Programs, CDC, 1095 

Willowdale Road, Morgantown, West 

Virginia 26505, (304) 285–5951; 

mgoldcamp@cdc.gov. 

The Chief Operating Officer, Centers for 

Disease Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for both 

the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2019–00198 Filed 1–25–19; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Fogarty International Center Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Fogarty International 

Center Advisory Board. The meeting 

will be open to the public as indicated 

below, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Fogarty International 

Center Advisory Board. 

Date: February 11–12, 2019. 

Closed: February 11, 2019, 1:00 p.m. to 

5:00 p.m. 

Agenda: Second level review of grant 

applications. 

Place: National Institutes of Health, 

Lawton L. Chiles International House, 

Building 16, Conference Room, 16 Center 

Drive, Bethesda, MD 20892. 

Open: February 12, 2019, 9:00 a.m. to 3:00 

p.m. 

Agenda: Update and discussion of current 

and planned FIC activities. 

Place: National Institutes of Health, 

Lawton L. Chiles International House, 

Building 16, Conference Room, 16 Center 

Drive, Bethesda, MD 20892. 

Contact Person: Kristen Weymouth, 

Executive Secretary, Fogarty International 

Center, National Institutes of Health, 31 

Center Drive, Room B2C02, Bethesda, MD 

20892, (301) 496–1415, weymouthk@

mail.nih.gov. 

This meeting notice is being published less 

than 15 days in advance of the meeting due 

to the partial Government shutdown of 

December 2018. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http://

www.fic.nih.gov/About/Advisory/Pages/ 

default.aspx, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.106, Minority International 

Research Training Grant in the Biomedical 

and Behavioral Sciences; 93.154, Special 

International Postdoctoral Research Program 

in Acquired Immunodeficiency Syndrome; 

93.168, International Cooperative 

Biodiversity Groups Program; 93.934, Fogarty 

International Research Collaboration Award; 

93.989, Senior International Fellowship 

Awards Program, National Institutes of 

Health, HHS) 


amozie on DSK3GDR082PROD with NOTICES1